Published in Hepatitis Weekly, July 27th, 1998
Under the terms of the agreement, Chiron markets and sells products that utilize Chiron's intellectual property relating to hepatitis C (HCV) and HIV and Gen-Probe's patented transcription-mediated amplification (TMA), target capture, hybridization protection assay (HPA) and dual kinetic assay (DKA) technologies.
Gen-Probe is scheduled to complete, in 1998, the development of the first...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.